Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 54,345 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the sale, the insider directly owned 132,873 shares in the company, valued at $1,696,788.21. This trade represents a 29.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Adam Crystal also recently made the following trade(s):

• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The shares were sold at an average price of $12.26, for a total value of $226,221.52.

Tango Therapeutics Price Performance

Shares of TNGX traded down $0.26 during mid-day trading on Friday, reaching $11.14. 1,845,900 shares of the company’s stock traded hands, compared to its average volume of 3,064,300. The stock’s 50-day moving average is $11.35 and its two-hundred day moving average is $9.20. Tango Therapeutics, Inc. has a 12 month low of $1.03 and a 12 month high of $13.60. The stock has a market cap of $1.50 billion, a P/E ratio of -11.98 and a beta of 1.75.

Institutional Trading of Tango Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. increased its holdings in shares of Tango Therapeutics by 138.8% in the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after acquiring an additional 40,983 shares during the period. AQR Capital Management LLC purchased a new position in Tango Therapeutics in the first quarter valued at about $195,000. Dynamic Technology Lab Private Ltd grew its stake in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares during the last quarter. Woodline Partners LP raised its holdings in Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after purchasing an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Tango Therapeutics by 270.6% during the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock valued at $483,000 after buying an additional 257,668 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Guggenheim boosted their price target on Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Friday, February 6th. Mizuho started coverage on Tango Therapeutics in a research note on Monday. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Wolfe Research assumed coverage on Tango Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.50.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.